Eko’s murmur detection algorithm was clinically validated in a Massachusetts General Hospital study. Credit: Copyright ©2024 Eko Health, Inc. All rights reserved.

Digital health company Eko Health has secured $41m in a Series D funding round to scale its AI-powered heart and lung disease detection.

The latest financing round comprised contributions from ARTIS Ventures, NTTVC, Highland Capital Partners, and Questa Capital.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This investment will facilitate the expansion of the company’s disease detection platform in the US and across the globe.

The latest funding round builds on certain commercial and clinical milestones, including clearances from the US Food and Drug Administration (FDA) for Eko’s structural heart murmur and low ejection fraction (Low EF) detection algorithms.

The murmur detection algorithm has been clinically validated in a study conducted at the Massachusetts General Hospital and demonstrated to boost identification rates of structural heart murmurs two-fold compared to standard practice used in primary care settings.

Eko developed the low EF detection algorithm in collaboration with Mayo Clinic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An Imperial College London study has shown that this algorithm improves the identification of heart failure with reduced ejection fraction in general practitioner clinics.

The company noted that implementing such AI-driven tools is critical in reducing diagnostic bottlenecks and enhancing patient outcomes.

With the infusion of new capital, Eko plans to deepen its market presence in the US and accelerate its expansion into key international markets.

These efforts will be supported by investments from Double Point Ventures in the US, global investor EDBI based in Singapore, and LG Technology Ventures.

Eko Health CEO and co-founder Connor Landgraf said: “Eko harnesses AI to unlock universal access to expert-level cardiac and pulmonary disease detection for patients everywhere.

“Just as Ring transformed doorbells into home security systems, Eko has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices.”

In September 2023, Eko Health and FIGS formed a partnership to unveil the new FIGS | Eko CORE 500 Digital Stethoscope.